Kelsey Goodwin
Stock Analyst at Piper Sandler
(4.89)
# 278
Out of 5,040 analysts
97
Total ratings
64.4%
Success rate
50.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Reiterated: Hold | $24 | $22.57 | +6.34% | 5 | Oct 1, 2026 | |
| SMMT Summit Therapeutics | Reiterated: Hold | $16 | $17.17 | -6.81% | 7 | Sep 29, 2026 | |
| LONA LeonaBio | Reiterated: Buy | $20 | $5.75 | +247.83% | 4 | Sep 21, 2026 | |
| OLMA Olema Pharmaceuticals | Reiterated: Buy | $40 | $7.82 | +411.51% | 5 | Aug 20, 2026 | |
| ERAS Erasca | Reiterated: Buy | $18 → $22 | $15.46 | +42.30% | 6 | Aug 12, 2026 | |
| CGON CG Oncology | Reiterated: Buy | $82 → $85 | $63.26 | +34.37% | 9 | Aug 7, 2026 | |
| JANX Janux Therapeutics | Reiterated: Buy | $26 | $18.50 | +40.54% | 8 | Aug 7, 2026 | |
| RLMD Relmada Therapeutics | Reiterated: Buy | $12 | $3.17 | +278.55% | 3 | Aug 7, 2026 | |
| BDTX Black Diamond Therapeutics | Reiterated: Buy | $8 | $1.81 | +341.99% | 5 | Aug 6, 2026 | |
| RVMD Revolution Medicines | Reiterated: Buy | $172 → $210 | $188.12 | +11.63% | 9 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $42 | $12.24 | +243.14% | 1 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $22 | $12.03 | +82.88% | 7 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $2.65 | +805.66% | 7 | May 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $36.98 | +8.17% | 8 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.78 | - | 1 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $36 | $17.26 | +108.57% | 2 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.46 | n/a | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $2.50 | n/a | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $13.31 | n/a | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $3.55 | n/a | 1 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $18.71 | n/a | 1 | Oct 31, 2022 |
Tango Therapeutics
Oct 1, 2026
Reiterated: Hold
Price Target: $24
Current: $22.57
Upside: +6.34%
Summit Therapeutics
Sep 29, 2026
Reiterated: Hold
Price Target: $16
Current: $17.17
Upside: -6.81%
LeonaBio
Sep 21, 2026
Reiterated: Buy
Price Target: $20
Current: $5.75
Upside: +247.83%
Olema Pharmaceuticals
Aug 20, 2026
Reiterated: Buy
Price Target: $40
Current: $7.82
Upside: +411.51%
Erasca
Aug 12, 2026
Reiterated: Buy
Price Target: $18 → $22
Current: $15.46
Upside: +42.30%
CG Oncology
Aug 7, 2026
Reiterated: Buy
Price Target: $82 → $85
Current: $63.26
Upside: +34.37%
Janux Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $26
Current: $18.50
Upside: +40.54%
Relmada Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $12
Current: $3.17
Upside: +278.55%
Black Diamond Therapeutics
Aug 6, 2026
Reiterated: Buy
Price Target: $8
Current: $1.81
Upside: +341.99%
Revolution Medicines
Aug 6, 2026
Reiterated: Buy
Price Target: $172 → $210
Current: $188.12
Upside: +11.63%
Aug 4, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $12.24
Upside: +243.14%
Aug 4, 2026
Rated: Buy
Price Target: $22
Current: $12.03
Upside: +82.88%
May 20, 2026
Reiterated: Buy
Price Target: $24
Current: $2.65
Upside: +805.66%
Apr 20, 2026
Reiterated: Buy
Price Target: $40
Current: $36.98
Upside: +8.17%
Mar 26, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.78
Upside: -
Dec 8, 2025
Reiterated: Buy
Price Target: $36
Current: $17.26
Upside: +108.57%
May 15, 2025
Reiterated: Buy
Price Target: $5
Current: $1.46
Upside: n/a
May 7, 2025
Reiterated: Buy
Price Target: $8
Current: $2.50
Upside: n/a
Apr 1, 2025
Reiterated: Hold
Price Target: n/a
Current: $13.31
Upside: n/a
Jul 30, 2024
Downgraded: Hold
Price Target: n/a
Current: $3.55
Upside: n/a
Oct 31, 2022
Initiated Coverage: Hold
Price Target: n/a
Current: $18.71
Upside: n/a